Home・Elenco Azioni・Ocugen Inc

Ocugen Inc

Chiusa

1.66 11.41

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.51

Massimo

1.67

Metriche Chiave
By Trading Economics
Entrata	-1.5M -19M
Vendite	1.7M 1.5M
EPS	-0.06
Margine di Profitto	-1,250.946
Dipendenti	116
EBITDA	-987K -17M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+544.67% upside

Dividendi
By Acuity
Utili prossimi	31 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-190M 437M
Apertura precedente	-9.75
Chiusura precedente	1.66

Ocugen Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

28 giu 2026, 23:51 UTC

Bitcoin dips while Ethereum rises amid investor caution over stock market leverage and upcoming AI earnings reports.

28 giu 2026, 23:51 UTC

Japan's retail sales data reveals consumer spending trends amid rising concerns over stock market leverage and volatility, as investors brace for upcoming U.S. Non-Farm Payrolls report.

28 giu 2026, 23:51 UTC

Bitcoin dips while Ethereum rises amid investor concerns over high leverage and volatility in equity markets, with key U.S. economic data expected to influence market dynamics.

28 giu 2026, 23:51 UTC

Bitcoin dips as Ethereum rises amid concerns over high leverage in stock markets and anticipation of Meta's earnings report, with key economic data releases on July 2 expected to impact Federal Reserve policy.

28 giu 2026, 23:51 UTC

ECB Forum on Central Banking Set for June 29, 2026: Focus on Monetary Policy and Interest Rates Amid Economic Uncertainties.

28 giu 2026, 23:51 UTC

Macro News

Bitcoin is lower as geopolitical tensions rise and South Korean stocks decline. It is currently about 5.32% below its 20-day moving average.

28 giu 2026, 23:41 UTC

Japan's Retail Sales Expected to Rise 3.2% in May, Boosting Investor Confidence Amid Global Market Concerns

28 giu 2026, 23:41 UTC

Avalanche is higher today, continuing its modest gain since Saturday's close. The price has fluctuated within a narrow range during the session.

28 giu 2026, 23:41 UTC

The FTSE 100 Index is lower after market hours, reflecting cautious investor sentiment amid rising concerns over high leverage and increased equity financing costs.

28 giu 2026, 23:32 UTC

Macro News

Correlated Moves

Ethereum is trading lower amid heightened geopolitical tensions and stock market volatility. Earlier in the session, it rebounded from a session high.

28 giu 2026, 23:22 UTC

Market Awaits BoE Governor Bailey's Speech on Interest Rates Amid AI-Driven Financial Stability Concerns.

28 giu 2026, 23:22 UTC

Market Awaits U.S. Average Hourly Earnings Data Amid Wage Legislation Debates and AI Sector Concerns Impacting Federal Reserve Policy.

28 giu 2026, 23:22 UTC

U.S. Labor Force Participation Rate Report Set for July 2, Amid Employee Dissatisfaction and Minimum Wage Legislation Debates

28 giu 2026, 23:22 UTC

Investors Brace for Insights on Interest Rates as BoC Governor Macklem's Speech Approaches Amid Economic Challenges in Canada

28 giu 2026, 23:22 UTC

U.S. Unemployment Rate Expected to Hold Steady at 4.3% Ahead of July 2 Release Amid Employee Dissatisfaction and Potential Minimum Wage Legislation

28 giu 2026, 23:22 UTC

U.S. Non Farm Payrolls Report on July 2 Forecasts 114K Job Additions Amid Cautious Market Sentiment and Legislative Changes Impacting Labor Dynamics.

28 giu 2026, 23:22 UTC

Market Awaits June 2026 Average Hourly Earnings Data Amidst Wage Growth Concerns and Legislative Push for Minimum Wage Increase.

28 giu 2026, 23:12 UTC

Mexico's Consumer Confidence Index set for July 3, 2026 release amid declining sentiment and cautious market expectations.

28 giu 2026, 23:11 UTC

GBP/CHF remains roughly flat during after-market hours, trading within a routine range since Friday's close amid concerns over high leverage in the stock market.

28 giu 2026, 23:11 UTC

SGD/CHF is trading roughly flat in after-market hours, remaining near the upper end of its one-month range amid broader market volatility concerns.

28 giu 2026, 23:11 UTC

Correlated Moves

USD/SEK remains roughly flat in after-market hours amid concerns about high leverage in the stock market and its impact on volatility.

28 giu 2026, 23:11 UTC

Correlated Moves

CHF/HKD trading remains roughly flat during after-market hours amid concerns over high stock market leverage and increased volatility in equity financing costs.

28 giu 2026, 23:01 UTC

Gold and silver prices are trading higher during the ongoing session, remaining above their 20-day moving average and near the upper end of their one-month range.

28 giu 2026, 23:01 UTC

Correlated Moves

Silver/CHF is lower today, following a decline from earlier highs. The asset trades below its 20-day moving average amid shifting market sentiment and increased volatility.

28 giu 2026, 23:01 UTC

Correlated Moves

Silver/GBP is lower today, reflecting declines in correlated assets like gold. Prices have fluctuated notably, currently near the lower end of its one-month range.

28 giu 2026, 23:01 UTC

Macro News

US 10Y Treasury Bond Index advances amid escalating Middle East tensions and lower oil prices, reflecting cautious investor sentiment near the upper trading range.

28 giu 2026, 23:01 UTC

The US 5Y Treasury Bond Index is trading higher, reflecting increased activity. It remains near the upper end of its one-month trading range.

28 giu 2026, 23:01 UTC

Macro News

Tensions between the U.S. and Iran have reportedly eased, potentially influencing global oil markets. The US 2Y Treasury Bond Index is trading roughly flat.

28 giu 2026, 23:01 UTC

Correlated Moves

Silver/SGD is trading lower, reflecting a challenging market environment and notable volatility. The asset remains significantly below its 20-day moving average.

28 giu 2026, 23:01 UTC

Correlated Moves

Silver/JPY is lower today, reflecting notable volatility and trading near the lower end of its one-month range. The asset is approximately 9.98% below its 20-day moving average.

Confronto tra pari

Modifica del prezzo

Ocugen Inc Previsione

Obiettivo di Prezzo

By TipRanks

544.67% in crescita

Previsioni per 12 mesi

Media 9.67 USD 544.67%

Alto 12 USD

Basso 7 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Ocugen Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 6 che hanno fornito valutazioni azionarie a Ocugen Inc - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.